A RandoMised study of best Available therapy versus JAK Inhibition in patients with high risk Polycythaemia Vera or Essential Thrombocythaemia who are resistant or intolerant to HydroxyCarbamide.

Trial Profile

A RandoMised study of best Available therapy versus JAK Inhibition in patients with high risk Polycythaemia Vera or Essential Thrombocythaemia who are resistant or intolerant to HydroxyCarbamide.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Essential thrombocythaemia; Polycythaemia vera
  • Focus Therapeutic Use
  • Acronyms MAJIC
  • Most Recent Events

    • 26 Oct 2017 Results published in the Blood
    • 26 Oct 2017 Primary endpoint (Complete Response rates, MAJIC-ET) has not been met as per the results published in the Blood.
    • 26 Oct 2017 Results (n=112) published in the Blood
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top